SMARTER PRECLINICAL PLANNING FOR BIOTECHS AND INVESTORS

THE PROBLEM

NAVIGATING THE PRECLINICAL MAZE

Early-stage biotech programmes routinely lose time, capital and credibility not because the science is weak, but because preclinical planning and regulatory execution are fragmented. Decisions are made across consultants, CROs and documentation; assumptions go untested; and capital is committed before risks are understood and interrogated. The result is avoidable waste, late regulatory surprises and reduced investor confidence.

NAVIGATING THE MAZE

our business

PreQlinic’s AI-enabled technology coupled with human expertise makes the preclinical process easier to navigate, more efficient and transparent. This helps biotech firms – and their investors – get treatment to patients faster, reduce waste and spend capital smartly.

HOW WE ADDRESS THE PROBLEM

OUR SOLUTION

PreQlinic provides structured, regulator-informed preclinical blueprints that empower scientific and regulatory teams to plan and execute with greater speed and confidence. Our proprietary knowledge base of regulated activities across CMC, bioanalysis, pharmacology, toxicology and regulatory domains, provides:

Integrated Roadmaps

Unite scientific, regulatory and operational planning into one connected framework, helping teams forecast costs, anticipate bottlenecks, optimise regulatory pathways and coordinate delivery with confidence.

EXPERT PERSONA INSIGHTS

Generative AI commentary, reviewed and validated by our multi-disciplinary specialists based on molecule, therapeutic area, route of administration, indication and other variables.

Investor readiness

Evidence-based documentation that demonstrates scientific rigour and strategic planning, transforms complex study data into clear, defensible narratives and aligns scientific milestones with commercial and regulatory goals that investors can trust.

NAMS (3RS) INTEGRATION

Validated alternatives that reduce, refine, or replace animal testing whilst aligning regulatory packages with EMA and FDA guidance, demonstrating ethical innovation and scientific robustness in every submission.

OUR team

The PreQlinic team has seen preclinical inefficiency from every angle – in science, regulation, operations and investment. Together, they bring experience across biosciences, technology integration, operations and stakeholder engagement – all driven by a shared goal: to make preclinical delivery as disciplined, transparent and intelligent as the science itself.

PERSPECTIVES FROM THE INDUSTRY

"PreQlinic is designed to support better scientific decisions earlier - before capital is locked in and options narrow. That combination of structure, transparency and human expertise is exactly what the industry needs."

This company stands out for its innovative technology, constructive attitude and genuine focus on getting medicines to patients more quickly and efficiently. As legal counsel, I’m naturally risk-aware and their approach appears thoughtful, credible and well suited to a highly regulated healthcare environment.”

“What attracted me to PreQlinic is its focus on fixing a structural problem in early drug development - not with noise or hype, but with discipline, transparency and proper execution.

"PreQlinic is building the kind of structured, regulator-aligned decision engine I wished every sponsor had"